

ARF promotes the degradation of the Epidermal Growth Factor Receptor by the lysosome

Anais Beaumont, Delphine Dayde, Anne-Sophie Hatat, Celine Barrial, Pascal Perron, Beatrice Eymin, Sylvie Gazzeri



PII: S0014-4827(18)30370-7  
DOI: <https://doi.org/10.1016/j.yexcr.2018.06.027>  
Reference: YEXCR11091

To appear in: *Experimental Cell Research*

Received date: 10 January 2018  
Revised date: 22 June 2018  
Accepted date: 23 June 2018

Cite this article as: Anais Beaumont, Delphine Dayde, Anne-Sophie Hatat, Celine Barrial, Pascal Perron, Beatrice Eymin and Sylvie Gazzeri, ARF promotes the degradation of the Epidermal Growth Factor Receptor by the lysosome, *Experimental Cell Research*, <https://doi.org/10.1016/j.yexcr.2018.06.027>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

# **ARF promotes the degradation of the Epidermal Growth Factor Receptor by the lysosome**

Anais Beaumont, Delphine Dayde, Anne-Sophie Hatat, Celine Barrial, Pascal Perron, Beatrice Eymin, Sylvie Gazzeri

Team “RNA splicing, cell signaling and response to therapies”, Institute for Advanced Biosciences, INSERM U1209, CNRS UMR 5309, Université Grenoble Alpes 38042 Grenoble Cedex 09, France

**Corresponding author:** Sylvie Gazzeri, Univ. Grenoble Alpes, INSERM U1209 – CNRS UMR 5309, Institute for Advanced Biosciences, Team RNA splicing, Cell signaling and Response to therapies, Allée des Alpes, 38700 La Tronche France. Tel.: +33 4 76 54 94 76; fax: 33 4 76 54 94 13. Sylvie.Gazzeri@univ-grenoble-alpes

## **Abstract**

Epidermal Growth Factor Receptor (EGFR) signaling regulates multiple cellular processes including proliferation, survival and apoptosis, and is attenuated by lysosomal receptor degradation. EGFR is a potent oncogene and activating mutations of EGFR are critical determinants of oncogenic transformation as well as therapeutic targets in non-small cell lung cancer. We previously demonstrated that wild type and mutant EGFRs repress the expression

Download English Version:

<https://daneshyari.com/en/article/8949692>

Download Persian Version:

<https://daneshyari.com/article/8949692>

[Daneshyari.com](https://daneshyari.com)